Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytarabine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    294 result(s) found for: Cytarabine. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-004896-60 Sponsor Protocol Number: LUMC2015-02 Start Date*: 2015-11-26
    Sponsor Name:Leiden University Medical Center
    Full Title: Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk
    Medical condition: Acute myeloid leukemia and high risk myelodysplasia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004982-32 Sponsor Protocol Number: LIPDEP-001 Start Date*: 2007-06-27
    Sponsor Name:Medical University of Vienna, Department of Pedatrics
    Full Title: Cerebrospinal fluid (CSF) and plasma pharmocokinetics of liposomal cytarabine (DepoCyte®) after intrathecal administration in children with malignant brain tumors and leptomeningeal dissemination
    Medical condition: To measure concentrations of liposomal cytarabine in CSF and plasma over time after intrathecal administration of liposomal cytarabine in children of different age groups with a malignant brain tum...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000344-42 Sponsor Protocol Number: AG-221-AML-004 Start Date*: 2016-01-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemi...
    Medical condition: Treatment of subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase 2 (IDH2) mut...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed) BE (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005241-20 Sponsor Protocol Number: F14512IN102G1 Start Date*: 2013-02-18
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Phase I-II study of F14512 in combination with cytarabine in patients 60 years old and older with acute myeloid leukemia.
    Medical condition: The scope of this study is the treatment of patient acute myeloid leukaemia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003065-15 Sponsor Protocol Number: WO29519 Start Date*: 2015-12-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTO...
    Medical condition: Relapsed or refractory acute myeloid leukemia (AML).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) NO (Completed) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001233-89 Sponsor Protocol Number: SGI-110-04 Start Date*: 2015-05-15
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for I...
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) BE (Completed) HU (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) CZ (Completed) AT (Completed) ES (Completed) PL (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013669-25 Sponsor Protocol Number: AEG35156-206 Start Date*: 2009-12-18
    Sponsor Name:Aegera Therapeutics Inc.
    Full Title: An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a S...
    Medical condition: Acute myeloid leukemia after failure of a single standard dose cytarabine based frontline induction regimen.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003444-20 Sponsor Protocol Number: AAML1421 Start Date*: 2017-08-24
    Sponsor Name:Children's Oncology Group
    Full Title: A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML).
    Medical condition: Acute myeloid leukemia recurrent
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012987 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-002964-25 Sponsor Protocol Number: GO40800 Start Date*: 2019-04-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IB/II STUDY, EVALUATING THE SAFETY AND EFFICACY OF IDASANUTLIN IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN PATIENTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) AND THE SAFETY A...
    Medical condition: Acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001588-22 Sponsor Protocol Number: AML003 Start Date*: 2019-07-04
    Sponsor Name:Rafael Pharmaceuticals, Inc.
    Full Title: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mi...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002822-19 Sponsor Protocol Number: B1371019 Start Date*: 2018-07-09
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN ...
    Medical condition: ACUTE MYELOID LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) SE (Completed) BE (Completed) PL (Completed) ES (Completed) DE (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-002487-27 Sponsor Protocol Number: 1230.14 Start Date*: 2013-01-21
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients ≥...
    Medical condition: previously untreated acute myeloid leukaemia in patients ≥ 65 years and ineligible for intensive remission induction therapy
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) GR (Completed) AT (Completed) FI (Completed) ES (Completed) IT (Completed) CZ (Completed) NL (Completed) HU (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005491-41 Sponsor Protocol Number: B1931022 Start Date*: 2012-06-13
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia...
    Medical condition: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) ES (Completed) GB (Completed) DE (Completed) FI (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009457-13 Sponsor Protocol Number: StudyITCC020&I-BFMRelapsedAML Start Date*: 2009-07-30
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
    Medical condition: Relapsed/refractory acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066638 Acute myeloid leukemia progression LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) AT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002345-39 Sponsor Protocol Number: Göteborg University Start Date*: 2006-02-16
    Sponsor Name:NOPHO NHL-group
    Full Title: B-NHL BFM 04
    Medical condition: B-cell lymphoma or B-ALL in children up to 18 years of age
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000699-24 Sponsor Protocol Number: PHRC2010-03 Start Date*: 2014-10-02
    Sponsor Name:CHU Angers-DAMR
    Full Title: Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à do...
    Medical condition: Leucémie aiguë myéloïde
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001043-19 Sponsor Protocol Number: CLO-34100405 Start Date*: 2008-09-24
    Sponsor Name:Genzyme Europe BV
    Full Title: Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) who have...
    Medical condition: Acute Myelogenous (Myeloid) Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000319-15 Sponsor Protocol Number: FLUGAZA Start Date*: 2014-07-25
    Sponsor Name:Fundación PETHEMA
    Full Title: A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza®) versus fludarabine plus cytarabine in elderly patients with newly diagnosed acute myeloid leukemia.
    Medical condition: Newly diagnosed acute myeloid leukemia.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005866-32 Sponsor Protocol Number: LAMSA2020 Start Date*: 2021-12-09
    Sponsor Name:FILO
    Full Title: A phase II randomized study to assess the efficacy on outcome of Venetoclax combined with Cytarabine versus Idarubicin combined with Cytarabine administered as post-remission therapy to elderly pat...
    Medical condition: elderly patients (> = 60 years) with Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004890-28 Sponsor Protocol Number: AC220-007 Start Date*: 2014-06-18
    Sponsor Name:Daiichi Sankyo Inc
    Full Title: A Phase 3 Open-Label Randomized Study of Quizartinib Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-li...
    Medical condition: Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Ongoing) IT (Completed) NL (Completed) ES (Ongoing) BE (Completed) HU (Completed) CZ (Completed) HR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 15:25:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA